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ABSTRACT Detailed molecular defmitlon of tbe WAGR 
region at chromosome llp13 bas been achleved by chromosome 
breakpoint analysis and long-range restrictlon mapping. Here 
we describe the molecular detedlon of a cytogenetlcally iDvis· 
ible l·megabase deletion ln an individual with anlridia, cryp· 
torcbiciism, and bypospadias but no WUms tumor (WT). The 
reglon of overlap between this deletion and one assodated witb 
WT and simUar genital anomalles but no anlridla covers a 
reglon of 350-400 kilobases, wblcb ls colncldent wlth the extent 
of homozygous deletlon detected in tumor tissue from a spo· 
radle WT. A candidate WT gene located wlthin this reglon has 
recently been isolated, suggesting nonpenetrance for tumor 
expression in the rarst iDdividual. The inclusion within tbe 
overlap region of a gene for WT predlsposltion and a gene for 
the best-documented WT -assodated genitourinary malforma· 
tions Ieads us to soggest that botb ofthese anomaUes result from 
a loss-of-function mutation at the same locus. Tbis in turn 
implies that the WT gene exerts plelotropic effect on both 
kidney and genitourinary development, a posslbUlty supported 
by the observed expresslon a)attern of the WT candidate gene ln 
developing kidney and gonads. 
Wilms tumor (WT) is a kidney malignancy-the most fre-
quently seen solid tumor of childhood. Most cases are 
sporadic and unilateral, with no associated anomalies. Bilat-
eral and familial tumors, comprising approximately 7% and 
1% of the incidence, respectively (1), have an earlier age of 
onset than unilateral cases. On the basis of such statistics, the 
two-hit hypothesis formulated originally for retinoblastoma 
was extended to WT (2). This model suggests that two 
mutational steps are required for the development of these 
childhood tumors. In the hereditary (bilateral and familial) 
cases, the first predisposing mutation is postulated to be 
present already in the germ-line and therefore present con-
stitutively in all cells of the target tissue-hence, the earlier 
age of onset. In sporadic cases, two mutations have to 
accumulate postzygotically within the same target cell. N ine-
ty-five percentofall WT cases have presented by the age of 
10 years (1), suggesting that the target-cell population disap-
pears as development to mature form is completed. 
Apart from rare familial incidence, the most clear-cut 
evidence for the presence of a predisposing DNA-Ievel 
change has come from the unexpectedly frequent association 
(1 in 100) of WT with aniridia (absence of iris) (3). After this 
Observation, the diagnosis of sporadic aniridia in newbom 
infants, especially when accompanied by other anomalies, 
became a prognostic indicator for the possible development 
of WT. In many such cases, additional genitourinary abnor-
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malities and mental retardationarealso present-hence, the 
acronym W AGR for this syndrome. Karyotypic analysis of 
WAGR cases revealed the frequent presence of a deletion on 
one .chromosome 11 homolog, always including part of band 
llpl3 (4). Only about 60% ofthe cases with a visible deletion 
develop WT, demonstrating that there is incomplete pene-
trance-presumably because no second mutation has oc-
curred, although it should be bome in mind that deletions that 
do not include the WT locus may exist. However, genitouri-
nary abnormalities, particularly in affected males, are seen at 
increased frequency, even in cases of sporadic WT, where no 
evidence of deletion can be found (M. M. Weil and D. A. 
Compton, personal communication; D. E. Housman, T. M. 
Glaser, and J. Pelletier. personal communication). There is 
also strong statistical evidence that genital- and kidney I 
urinary-system abnormalities are associated with early-onset 
(more frequently bilateral) WTs and with intralobar nephro-
blastomatosis (1, 5). These associated anomalies are all 
hallmarks of the .. hereditary" tumor arising when there is a 
preexisting germ-line mutation. Therefore, their existence 
may result from the dominant etTects of constitutional mu-
tation-the first "hit" at the WT locus. 
In the course of localizing accurately and eventually clon-
ing the genes ofthe WAGR region, using a number of deletion 
and translocation breakpoints, we have carried out molecular 
analysis of the llpl3 region in a child with incomplete WAGR 
syndrome. His abnormaJities comprise aniridia, genitouri-
nary abnormalities, and mental retardation but no WT. 
Hybrid cell analysis and pulsed-field gel electrophoresis 
(PFGE) with previously mapped markers for the region 
revealed the loss of around 1 megabase (Mb) from one 
chromosome 11 homolog in this case, although no cytoge-
netic abnormality was visible. 
Detailed molecular analysis also has been carried out on a 
second patient with a visible deletion at chromosome llpl3, 
who had WT, genitourinary abnormalities, but no aniridia 
(6-8). The smallest region of overlap between these two 
deletions coincides with the extent of a rare WT -associated 
homozygous deletion region (9, 10) and includes the putative 
WT locus, for which a candidate genewas recently isolated 
(11). From the clinical observations in these two constitu-
tional deletion patients, the overlap region must also contain 
the gene(s) whose deletion Ieads to the associated genitouri-
nary abnormalities. 
On the basis of these results, we soggest that the WT gene 
may have pleiotropic effects on both kidney and genital 
Abbreviations: WT, Wilms tumor; WAGR, WT with aniridia, gen-
itourinary anomalies, and mentaJ retardation triad; WT, gene for WT; 
AN2, chromosome llpl3-associated aniridia 2 gene (without WT, 
genitourinary anomaJies, and mental retardation); PFGE, pulsed-
field gel electrophoresis; FSHB, gene for follicle-stimulating hor-
mone ß; CALC, gene for calcitonin; CAT, gene for catalase. 
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development, at least in males. This idea is supported by the 
elevated frequency of genitourinary anomalies accompany-
ing WT and by the common embryological origins of the 
genital system and the metanephric kidney. The argument in 
favor ofthisdual role for the WT gene in the development of 
both the kidney and genital system is further strengthened by 
the pattem of expression of the recently isolated candidate 
gene for the WT locus. 
MATERIALSAND METHODS 
Clinical Summary and Cytogenetic Analysis. The patient, 
PAZO, presented initially with sporadic aniridia. Subse-
quently cryptorchidism (undescended testes) and hypospa-
dias (misplaced penile extemal urinary orifice) were noted. 
Mild mental retardation and developmental delay were ob-
served. No WT has been found in this boy, now age 12. 
Karyotype analysis of chromosome preparations from pe-
ripheral blood and later from the Epstein-Barr virus-
transformed lymphoblastoid cellline (12) revealed no abnor-
malities. In particular no deletion was detected on the chro-
mosome 11 short arm. 
The second patient, DAR, has been described in detail (13). 
He presented with WT at age 21 months. There was no sign 
of aniridia or cataract. He required surgery to correct abnor-
mal extemal genitalia: chordee (abnormally curved penis) 
and bilateral cryptorchidism. Karyotype analysis of chromo-
somes from peripheral blood cultures revealed deletion of 
most of band 11p13. Catalase activity was reduced, suggest-
ing deletion of the locus CAT encoding this enzyme. 
Somatic Cell Hybrids. Fusions were carried out between 
Epstein-Barr virus-transformed lymphoblastoid cells from 
the patients and mouse myeloma celllines as described (6, 
12). Stable celllines were selected by fluorescence-activated 
cell sorting and subcloning of live cells with high-level 
expression of appropriate human chromosome 11-encoded 
cell surface markers (6, 14). The newly produced hybrids 
from the PAZO cell line were designated PAX and were 
analyzed for heterozygous marker alleles to ensure the pres-
ence of each chromosome 11 homolog in independent hy-
brids. DAR 15.4 has beeri described (6). 
DNA Markers. The derivation and characterization of the 
DNA markei's used in these analyses have been described in 
detail as follows: probes specific for follicle-stimulating hor-
mone ß gene (FSHB), for the calcitonin gene (CALC), for 
CAT, and for monoclonal antibody markers for MIC/1 and 
MIC4 (14); DIISI6 (15); L65-6/74 (D/IS/12), C65-6/6 
(DJISI02), L65-6/228 (DIISI07), and P9RH (16); 582 
(DI IS317), 495 (DI ISJIO), M20 (DI IS377) (7); p5 (DI IS323) 
(17); Sl (DI I S87) (9); NBC12 (DI I S294) (8); LP2G4 
(DIIS48), LP4F11 (DJJS82), LP11F9 (DIIS49) (18); and 
Dl IS9 (19). 
Repeat-free probes used in this study have been described 
(8). Additionally, JM44 is a 4.4-kilobase (kb) BamHI frag-
ment from L65-6/74 DNA marker subcloned into pBiue-
scribe. 
PFGE. High molecular weight DNA was prepared, and 
PFGE was perfoi'med as described (8). Size markers were 
oligomers of phage A DNA and chroniosomes of Saccharo-
myces cerevisiae, strain YPH 148. 
RESULTS 
A series of PAX hybrids werc produced from the PAZO 
lymphoblastoid cell line known to be heterozygous for the 
polymorphic marker CALC. Analysis of these hybrids re-
vealed that one allele was present in PAX 1 and the altemate 
allelein PAX 17, thus demonstrating the separation ofthe two 
chromosome 11 homologs (Fig. la). 
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Fao. 1. Deletion mapping by DNA blot anaJysis in somatic ccll 
hybrids. Digested DNA was loaded for hybrids (10 #Ai) and species 
controls (5 1-'g). "11-only'' denotes a control somaticcell hybrid with 
chromosome 11 as its sole human component. Thermus aquaticus 
Taq I digests were probed for CALC polymorphism (a), and liamHl 
digests were probed for DNA markers NBC12 (b), L65-6/74 (c), and 
Sl (d). 
Initial hybridization with available markers for the 11pl3 
region showed no evidence of deletion, even with DNA 
markers such as NBC12 and L65-6/74, which were located 
close to the WTand AN2 loci (8) (Fig. 1 band c). As further 
markers became available the hybrids were examined for 
their presence. In PAX 1, but not PAX 17, the markers Sl 
(Fig. ld) and 495 were deleted as weil as the intervening 
marker p5 (data not shown). Results are summarized in Fig. 
2, which illustrates the extent of deletions in the two patients 
described here. 
The physical map of the WAGR region, summarized in Fig. 
3, suggested that the DNA matkers NBC12 and L65~/74 
should closely flank the deletion in PAZO DNA (8). Char-
acterization of PAZO DNA by PFGE demonstrated that the 
proximal deletion breakpoint disrupts the 500-kb Not I frag-
ment hybridizing to NBC12 (Fig. 4B), although the proximal 
90-kb regionoftbis fragmentwas unaltered (data not shown). 
In a similar manner, the distal deletion breakpoint interrupts 
the 1.4-megabase (Mb) BssHII fragment [these CpG island 
sites are coincident with Not I sites (8, 20)] hybridizing to 
L65-6/74 (Fig. 4A). The presence of an unaltered Sac II 
fragment restricts the position of this breakpoint to the 
centromeric 400 kb of the BssHII (Not I) fragment (20). This 
fragment directly abuts the AN2 translocation, which has 
been studied in detail (21). 
The distal deletion breakpoint in the DAR parent lympho-
blastoid line cannot be localized precisely. No altered Not I 
fragment could be detected with probe p5, which therefore 
places the deletion breakpoint proximal to the 325-kb frag-
ment on which p5 resides (17). 
DISCUSSION 
Molecular analysis of llp13 has allowed several groups to 
delineate a consensus map of the DNA in the WAGR region 
(7, 8, 17, 20). In this study we have demonstrated the 
presence of a 1-Mb deletion in a patient with aniridia, 
hypospadias, cryptorchidism, and mental retardation but no 
WT. It is worth noting that a karyotypically undetectable 
deletion can involve loss of such a large amount of DNA. 
The smallest region that must contain the WT locus has 
been refined by the deletions in DAR and in WiT13 DNAs. 
DAR is an individual with WT, cryptorchidism, and mild 
hypospadias but without aniridia-the case that clearly dem-
onstrated the separate identities of the WT and AN2 genes, 
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FJG. 4. PFGE analysis ofthe PAZO DNA breakpoints. Position 
ofthe yeast size markers is indicated. (A) BssHll digestwas probed 
with the single-copy subclone of L65-6/74: homozygosity for the 
normal1.4-Mb fragment is seen in control DNA, while PAZO DNA 
is heterozygous fot the normal fragment on one homolog and a new 
smaller fragrrient on the deletion chromosome. (B) Not I digest was 
probed with the single-copy subclone of NBC12: homozygosity for 
the normal 500-kb fragment is seen in control DNA, while PAZO 
DN A is heterozygous for the normal fragment and an ..,.1.5-kb altered 
fragment. 
sporadic WT in a patient with no constitutional chromosome 
11 deletion. However, the tumor itself was shown to be 
homozygously deleted for the llp13 marker SI (9). Subse-
quentanalysis ofthe two chromosome 11 homologs revealed 
independent overlapping deletions (10). The region of ho-
mozygous deletion is presumed to include the WT locus, and 
its existence permitted the isolation of a strong candidate for 
the WTgene (11). Recently, homozygous deletions within the 
same small region were described in two further sporadic 
tumors and a second cloning of the same candidate WT gene 
was reported (23). 
lt is only in the light of the location of these homozygous 
tumor-associated deletions that we could conclude that the 
PAX1 
DAR15.4 
__ -""'! '--' ._1 f_ _"f!_f--'-1 '-------'--_ Not I 
F1o. 3. The consensus Iang-
range map of the chromosome 
llpl3 region. The size of the nor-
mal Not I fragments in kb is 
shown, with the positions of weil· 
characterized translocation break-
points marked by arrows. Aster-
isks denote the site of CpG islands 
associated with the ends of genes. 
The regions that must contain 
genes responsible for the observed 
phenotypes in the two deletions 
are shown as boxes. The coirici-
dence between the homozygous 
WiT13 tumor DNA deletion and 
the region of deletion overlap be-
tween PAZO and DAR DNAs is 
marked. The expected sizes of the 
altered PFGE fragments in PAZO 
DN A can be deduced from the 
position of the restriction sites 
shown. T-ALL. T-cell acute lym-
phocytic leukemia; GUD, geni-
tourinary dysplasia. 
_ _ I I I I I I _ _ BssH 11 
___ ..,~.1__..1 ... 1~.-1.....___..! ___.! __ .....__ __ __._-- Sac II 
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patient P AZO, although nonpenetrant for tumor expression, 
must Iack the WT locus. Therefore, the smallest region of 
ov~rlap between the proximal breakpoint in P AZO DNA and 
the distal one in DAR DNA includes the WT gene and covers 
almost exactly the same 350..kb region as the homozygous 
deletion in WiT13 DNA (10). lt is interesting to note that 
patients PAZO and DAR also share the hypospadias-crypt-
orchidism phenotype. This implies that a gene involved in 
aspects of male genital development also lies within the region 
of deletion overlap. Could it be that the gene involved in 
predisposition to WT also plays a roJe in genital development? 
The candidate WT gene of Call et al. (11) was generously 
made available to us. Wehave been studying the expression 
pattem of this gene in normal development of early embryos. 
At the Ievel of RNA blot analysis, expression is clearly seen 
in fetal testis and ovary in addition to developing kidney (11, 
29). mRNA in situ hybridization in early embryos confirms the 
tissue distribution, showing strong expression in both meta-
nephric and mesonephric kidney andin the early gonad (29). 
These results are consistent with the hypothesis that the WT 
gene may have pleiotropic etlects on both kidney and genital 
development. Since correct early gonadal function inßuences 
subsequent genital development, mutation in this gene could 
account for the high frequency of cryptorchidism and hypo-
spadias in male WT patients with or without aniridia (1, 5). 
In the case of aniridia-associated genitourinary abnormal-
ities (four of five males among our patients with llpl3 
deletion-associated aniridia, with or without WT, have crypt-
orchidism and/or hypospadias), the presence of a deletion 
(and therefore by definition a null allele) is implicated. It 
seems reasonable to suggest that similar genitourinary ab-
normalities seen in association with apparently "sporadic" 
WT are the result of germ-line or early zygotic mutation 
within the llpl3 region and perhaps within the single WT 
candidate locus. Since the candidate WT gene covers a 
genomic distance of only -so kb, there is room for other 
genes with influence on genital development in the 35().. to 
400-kb overlap region between the deletions ofthe PAZO and 
DAR DNAs. However, the pleiotropy hypothesis can now be 
tested by looking for germ-line mutations at the WT locus in 
appropriate patients. 
The possäble involvement of the WT candidate gene in 
gonadal development should be bome in mind when consid-
ering the documented Iack of affected offspring among 179 
children of 99 surviving unilateral WT patients (24). Such a 
large number of cases should include at least some with 
germ-line mutations (2). Absence of WT transmission could 
be explained by suggesting that s.uch a constitutional change 
might render the carrier infertile or the carrier gametes 
nonviable. Consistent with this idea, where linkage studies of 
familial WT have been done, no llpl3 association has been 
seen (25, 26). Countertothis suggestion, however, there is 
evidence of at least partial fertility from observations of the 
Dickie Smalleye (Seyl>) mouse, which carries a WAGR-like 
chromosome 2 deletion encompassing loci that include the 
WT candidate and Sey, which may be the mouse aniridia gene 
homolog (27). However, the validity ofthe mouse model for 
human disease may be questioned because the Sey0 mouse 
also shows no predisposition to kidney tumors (27). In 
addition, genetic control of fertility may ditler in mouse and 
man: for example, XO mice are usually fertile, while human 
XO individuals are virtually always sterile (28). 
To confirm involvement of the WT candidate gene in 
tumorigenesis and in genitourinary development, mutation 
analysis is required (i) at the mRNA or DNA Ievel in tumor 
tissue (11) and (ii) at the germ-line Ievel in candidate patients 
with WT accompanied by genitourinary anomalies. Only 
detailed functional analysis of this candidate gene-including 
the search for upstream control elements and downstream 
targets-will allow us to make the final conclusions about its 
Proc. Natl. Acad. Sei. USA 87 (1990) 
biological rote in both kidney and genital development. 
Meanwhile, the search continues for other genes of interest 
in this region of chromosome llp13. 
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